Kevin M. Brennan

Kevin M. Brennan is a declared insider of Xilio Therapeutics, Inc., with filings sourced from SEC (Form 4). We count 4 filings; the first trade dates from 1 January 2025 and the latest from 2 January 2026.

Sales make up the whole of the open-market record (2 sales, €2,713). Other entries cover 2 option exercises. In 2026 alone, the filings show no purchases and 1 sale.

On 5 January 2026 came the latest disclosure, an open-market sale for €1,000 in Xilio Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.